Clinical trials: Idiopathic Pulmonary Fibrosis(IPF)
Idiopathic Pulmonary Fibrosis
Daoyin Technique for Improving Exercise Endurance in IPF
This study is based on the previously constructed digital rehabilitation management platform, scientifically evaluating the clinical efficacy of guided technology in improving IPF exercise endurance, and forming high-quality…
- Trial name
- NCT07019714
- Testing
- Daoyin Technique, Routine Comprehensive Training
- Where
- 3 sites in China
- Volunteers
- 236 people
- Sponsor
- Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF)
Pulmonary Fibrosis Foundation Patient Registry
The Pulmonary Fibrosis Foundation Patient Registry will collect data on at least 2,000 patients with interstitial lung disease (ILD) at approximately 40 clinical sites in the US.
- Trial name
- PFFR (NCT02758808)
- Where
- 42 sites in United States
- Volunteers
- 2,004 people
- Sponsor
- Pulmonary Fibrosis Foundation
Idiopathic Pulmonary Fibrosis
A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 2, randomized, placebo controlled, multi-center study in subjects with mild to moderate IPF. Eligible subjects will be randomized to receive placebo or ENV-101 as a daily oral dose for 12 consecutive weeks of…
- Trial name
- NCT04968574
- Testing
- taladegib
- Where
- 24 sites in Australia, Canada and 3 more
- Volunteers
- 41 people
- Sponsor
- Endeavor Biomedicines, Inc.
Idiopathic Pulmonary Fibrosis
Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers
This is a randomized, open-label, 2-treatment, 2-period, crossover steady state study conducted to evaluate the comparative bioavailability/bioequivalence of pirfenidone after multi-dose administration of EXCL-100 at doses of…
- Trial name
- NCT05428150
- Testing
- Esbriet 267 MG Oral Capsule, EXCL-100, 600 MG Oral Tablet
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Excalibur Pharmaceuticals, Inc.
Interstitial Fibrosis, Pulmonary Disease
Inspiratory Muscle Training in Patients With Interstitial Lung Disease
The aim of this study is to evaluate the effects of inspiratory muscle training program in inspiratory muscle endurance, breathlessness, inspiratory muscle strength, functional capacity and quality of life in patients with…
- Conditions
- Interstitial Fibrosis, Pulmonary Disease, Interstitial Lung Disease, Sarcoidosis
- Trial name
- IMT-ILD (NCT04481074)
- Testing
- Inspiratory muscle training
- Where
- 2 sites in Brazil
- Volunteers
- 14 people
- Sponsor
- Federal University of Minas Gerais
Interstitial Lung Disease
Pulmonary Care and Research Collaborative Patient Registry
The purpose of this research study is to build and maintain a registry of people with interstitial lung disease (ILD). Medical information collected for this registry may be used to advance ILD and pulmonary research and improve…
- Trial name
- NCT05445817
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Pulmonary Care and Research Collaborative Limited
Idiopathic Pulmonary Fibrosis
Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/
A study in mild/moderate IPF patients using an αVβ6 PET ligand to evaluate target engagement.
- Trial name
- IPF-201 (NCT04072315)
- Testing
- PLN-74809, Knottin tracer
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Pliant Therapeutics, Inc.
Idiopathic Pulmonary Fibrosis, Cough
Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide
Idiopathic Pulmonary Fibrosis (IPF) is a rapidly progressive lung disorder that is often associated with a chronic, intractable cough.
- Trial name
- NCT00600028
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Johns Hopkins University
Idiopathic Pulmonary Fibrosis
Telenursing and Remote Monitoring in Idiopathic Pulmonary Fibrosis (IPF)
Numerous studies show that remote monitoring and/or telenursing improves outcomes for patients especially those with chronic diseases.
- Trial name
- NCT03562247
- Testing
- Usual Care of IPF, Telenursing, Telenursing and Remote Monitoring
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Vanderbilt University Medical Center
Idiopathic Pulmonary Fibrosis
Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg once daily or 600 mg twice daily for 26 weeks compared with placebo will reduce the decline in forced vital capacity (FVC) and will be well…
- Trial name
- NCT01766817
- Testing
- BMS-986020
- Where
- 72 sites in United States, Australia and 4 more
- Volunteers
- 325 people
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis
This is an interventional double-blind randomized controlled trial, to investigate the short and long-term effects of a supervised exercise training program in patients with IPF, depending on alternate patterns of oxygen…
- Trial name
- NCT03326089
- Testing
- Pulmonary rehabilitation
- Where
- Greece
- Volunteers
- 20 people
- Sponsor
- Corfu General Hospital
Idiopathic Pulmonary Fibrosis
A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are at least 40 years old. People taking standard medicines for IPF, including antifibrotic medicines, can continue taking them throughout the study.
- Trial name
- NCT04419506
- Testing
- BI 1015550
- Where
- 75 sites in United States, Argentina and 20 more
- Volunteers
- 147 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Study of ORJ-001 for the Treatment of IPF
ORJ-001 is a new class of drugs intended for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is a Phase 2 study in two parts; the objective of Part A will determine if ORJ-001 is well-tolerated by…
- Trial name
- NCT07869147
- Testing
- ORJ-001
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Oorja Bio, Inc.
Idiopathic Pulmonary Fibrosis, Pulmonary Disease
Influence of Socioeconomic and Environmental Factors on the Natural History of Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis(IPF) is the most common idiopathic interstitial lung disease whose cause is unknown. With age and gender, socio-economic factors are the most influential indicators of health.
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Disease, Pulmonary Medicine
- Trial name
- EXPOSOMFPI (NCT04619199)
- Testing
- Blood sample
- Where
- 16 sites in France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Interstitial Lung Disease (ILD), Suspected Interstitial Lung Disease
Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial
The OPTIMIZE-ILD-1 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated diagnostic pathway on patients with suspected interstitial lung disease (ILD).
- Conditions
- Interstitial Lung Disease (ILD), Suspected Interstitial Lung Disease, Fibrotic Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis (IPF)
- Trial name
- OPTIMIZE-ILD-1 (NCT07482917)
- Testing
- Standard ILD Diagnostic Pathway, Optimized ILD Diagnostic Circuit
- Where
- Spain
- Volunteers
- 92 people
- Sponsor
- Hospital de Granollers
IPF
Turkish Validity and Reliability of SGRQ-I
The Saint George Respiratory Questionnaire (SGRQ) questionnaire is a frequently used questionnaire in the respiratory patient group, and the Turkish version of this questionnaire, which was created for use in idiopathic pulmonary…
- Trial name
- NCT05147597
- Testing
- Questionnaire
- Where
- Turkey (Türkiye)
- Volunteers
- 180 people
- Sponsor
- Saglik Bilimleri Universitesi
Interstitial Lung Disease Due to Systemic Disease (Disorder), Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder)
Occupational and Environmental Exposures Analysis in Interstitial Lung Diseases.
The OCEAN-ILD study is designed to prospectively evaluate the prevalence and clinical relevance of environmental and occupational exposures in a large Italian cohort of patients affected by any ILD, using a standardised exposure…
- Conditions
- Interstitial Lung Disease Due to Systemic Disease (Disorder), Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder), Exposure Occupational, Occupational Exposure
- Trial name
- OCEAN-ILD (NCT07577115)
- Testing
- standard interview
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Istituto Clinico Humanitas
Idiopathic Pulmonary Fibrosis, Depression
Palliative Care and Quality of Life in Idiopathic Pulmonary Fibrosis
The purpose of this study is to evaluate the effects of adding a palliative care intervention for patients with idiopathic pulmonary fibrosis (IPF) to current standard of care.
- Conditions
- Idiopathic Pulmonary Fibrosis, Depression, Anxiety, Depressive Disorder
- Trial name
- NCT03981406
- Testing
- Palliative Care, Standard of Care
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Minnesota
Idiopathic Pulmonary Fibrosis
Changes in iOS in IPF
Idiopathic pulmonary fibrosis (IPF) is a condition where scar tissue (called fibrosis) builds up in the lungs. It usually gets worse over time.
- Trial name
- NCT04572958
- Where
- United Kingdom
- Volunteers
- 132 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Idiopathic Pulmonary Fibrosis
A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
The goal of this clinical trial is to learn about the potential effect of ENV-101 (taladegib) on the pharmacokinetics of nintedanib (an approved treatment for idiopathic pulmonary fibrosis) when the two compounds are dosed…
- Trial name
- NCT05817240
- Testing
- taladegib, nintedanib
- Where
- Australia
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Endeavor Biomedicines, Inc.